Related Experiment Video

Updated: Jun 18, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions

Shuting Li1, Hongjie Wang1, Shijun Xiong1,2

  • 1Xiangya School of Medicine, Central South University, Changsha 410011, China.

Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
PubMed

Insights

Targeted drug delivery systems show promise for treating multiple myeloma (MM) by improving drug efficacy and reducing side effects. This review examines antibody-drug conjugates, peptide-drug conjugates, aptamer-drug conjugates, and nanocarriers in MM treatment.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a common blood cancer with a poor prognosis.
  • Conventional chemotherapy for MM has limitations including side effects and drug resistance.

Purpose of the Study:

  • To review the performance of targeted drug delivery systems in multiple myeloma treatment.
  • To analyze antibody-drug conjugates, peptide-drug conjugates, aptamer-drug conjugates, and nanocarriers for MM.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of targeted drug delivery systems in multiple myeloma.
  • Monitoring of adverse reactions associated with these treatments.

Main Results:

  • Targeted drug delivery systems demonstrate potential for enhanced MM therapy.
  • Various conjugates and nanocarriers show promise in preclinical and clinical settings.
  • Adverse reactions are being monitored to ensure safety.

Conclusions:

  • Targeted drug delivery systems offer a promising strategy to improve MM treatment efficacy and safety.
  • Further research and clinical trials are essential to optimize these advanced therapies.
  • Overcoming traditional chemotherapy limitations is key for better MM patient outcomes.
Keywords:
drug delivery systemmultiple myelomatargeted therapy

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K